<DOC>
	<DOCNO>NCT01662531</DOCNO>
	<brief_summary>This study examine pharmacokinetics , safety efficacy rIX-FP control prevention bleed episode child previously receive factor replacement therapy hemophilia B .</brief_summary>
	<brief_title>A Safety , Efficacy Pharmacokinetics Study Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin ( rIX-FP ) Children With Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Male subject , young 12 year old . Severe hemophilia B ( Factor IX [ FIX ] activity ≤ 2 % ) . Body weight ≥ 10 kg . Subjects receive FIX product ( plasmaderived and/or recombinant FIX ) &gt; 150 exposure day ( EDs ) ( 6 &lt; 12 year ) , &gt; 50 EDs ( &lt; 6 year ) . No history FIX inhibitor formation , detectable inhibitor Screening family history inhibitor FIX . Written inform consent study participation . Known hypersensitivity FIX product hamster protein . Known congenital acquire coagulation disorder congenital FIX deficiency . Kidney liver disease . Recent lifethreatening bleed episode .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>